查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1933845

末期肾功能衰竭治疗市场按治疗类型、最终用户和分销管道划分，全球预测（2026-2032年）

End-stage Renal Disease Therapeutics Market by Therapy Type, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025年末末期肾功能衰竭治疗市值为670.5亿美元，预计2026年将成长至707.3亿美元，年复合成长率为4.17%，到2032年将达到892.9亿美元。

关键市场统计数据
基准年 2025 670.5亿美元
预计年份：2026年 707.3亿美元
预测年份 2032 892.9亿美元
复合年增长率 (%) 4.17%

全面实施末期肾功能衰竭护理：重点关注不断变化的临床重点、患者就医历程和跨学科护理整合

本概要概述了当代末期肾功能衰竭治疗的临床、运作和商业性层面。它重点介绍了重点患者群体、常见合併症和治疗路径衔接，并强调了药物治疗和肾臟替代疗法之间的相互作用。透过将治疗置于连续性照护框架中，它阐述了不断变化的实践模式、技术进步和支付方期望如何重塑治疗决策和医疗服务提供者的责任。

临床实践、报销模式以及技术赋能的家庭护理方面的变革性变化正在重塑不同护理机构中的患者就医途径和临床医生工作流程。

末期肾病治疗领域正经历多重变革，这些变革对医疗服务提供者、製造商和医疗保健系统都产生了影响。临床实践日益注重个别化治疗，治疗方案的选择综合考虑了患者的合併症情况、实际用药依从性以及家庭治疗的选择范围。同时，报销机制和政策调整正在重塑医疗服务的奖励，推动缩短住院时间、采用统一支付方式以及以结果而非数量为导向的价值导向合约。

预计2025年美国关税趋势将对肾臟药物供应链、筹资策略、成本结构和全球采购产生累积影响

预计2025年美国关税政策的累积影响将波及肾臟治疗药物的采购、生产和分销环节，但不会改变该疗法的临床原理。关税变化将影响进口原料药、透析耗材和资本财的成本基础，促使供应链管理人员重新评估采购区域并调整库存策略。为此，预计相关人员将更加重视供应商多元化、尽可能选择近岸外包以及采用双重采购策略，以降低对单一国家的依赖风险。

关键的细分洞察，整合了治疗领域、透析方式、终端用户给药途径和分销管道，为产品定位提供了宝贵的资讯。

关键的细分洞察突显了临床需求、营运可行性和商业性机会的交集，而这又基于治疗类别、给药方式和分销管道之间的相互作用。按治疗类型划分，药物治疗和肾臟替代疗法是重点领域。在药物治疗方面，主要药物类别——钙敏感受体激动剂、促红血球生成素、铁剂、磷酸盐粘合剂和维生素D类似物——在疗效、安全性和给药方式方面各有优劣，这些优劣会影响处方决策和依从性计画。肾臟替代疗法包括血液透析、腹膜透析和肾臟移植。血液透析再细分为居家透析和中心透析，腹膜透析则细分为自动腹膜透析和持续性携带式透析。这些治疗方法之间的差异对于设备相容性、培训需求和急性后期护理协调至关重要。

美洲、欧洲、中东和非洲以及亚太地区的战略区域观点重点关注医疗服务取得趋势、临床基础设施和政策槓桿。

区域洞察揭示了政策环境、临床基础设施和患者人口结构如何影响美洲、欧洲、中东和非洲以及亚太地区的医疗服务模式和营运实践。在美洲，医疗服务通常需要在先进的中心透析能力与日益增长的家庭治疗和移植计画需求之间取得平衡。这主要由强调协调慢性病管理的支付者和综合医疗网络推动。要在此基础上进行转变，製造商和服务供应商需要建立客製化的合作策略，以反映不同的支付方模式和集中化的卓越中心。

领先製造商、技术提供者和服务网路之间的竞争和联盟动态正在推动创新、试验设计和商业化策略。

对主要企业的深入分析凸显了竞争定位、合作联盟和服务差异化如何塑造创新轨迹和市场行为。领先的製造商和技术供应商正在加速将其药品组合与医疗设备和数位化赋能相结合，以提供能够同时解决临床疗效和依从性障碍的综合解决方案。这种整合也延伸至与学术机构和医疗系统在临床试验设计方面的伙伴关係，从而能够产生可操作的证据，证明其在不同医疗环境中的真实疗效。

为实现可衡量的营运和临床改进，提出切实可行的建议，以协调临床开发、供应链韧性和以患者为中心的服务模式。

切实可行的建议鼓励行业领导者将临床开发、营运韧性和以患者为中心的医疗服务相结合，以创造永续价值并改善治疗效果。首先，优先考虑可适用于血液透析、腹膜透析和移植治疗路径的模组化产品和服务设计，确保临床证据的生成能够满足每种治疗方法的独特终点。其次，透过采购多元化策略、提高对一级和二级供应商的透明度以及建立能够分散海关和物流风险并维持品管的合约框架，来增强供应链韧性。

稳健的混合方法调查方法：资料来源、相关人员参与、检验过程和分析架构均有明确的定义，以确保研究的严谨性和相关性。

为确保调查方法采用混合方法，结合了与关键相关人员的直接对话、二手文献综合分析和质性检验。直接对话包括与临床医生、采购专业人员、支付方和技术合作伙伴进行结构化访谈，以收集关于治疗选择、模式采纳和分销实践的实际观点。这些访谈为假设驱动型问卷的製定提供了依据，并有助于对营运挑战和创新重点进行三角验证。

一份全面的综合报告，重点阐述了尚未满足的需求、转换差距和策略转折点，旨在指导研发、商业化和支付方参与计划。

总之，目前末期肾功能衰竭治疗面临多重交织的压力和机会，需要临床、商业和营运等相关人员的协调应对。在优化贫血管理、控制矿物质和骨骼疾病、以及从透析到肾臟移植的以患者为中心的护理服务等方面，仍存在诸多未满足的需求；此外，在将基于设备和数位化的干预措施从试点阶段推广到常规临床实践方面，也存在转化方面的差距。策略转折点包括扩大家庭治疗方法、推出整合治疗和服务的捆绑式解决方案，以及根据关税和地缘政治风险调整供应链。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 依治疗类型末期肾功能衰竭治疗市场

  • 药物治疗
    • 钙模拟物
    • 红血球生成刺激因子
    • 铁剂治疗
    • 磷酸盐粘合剂
    • 维生素D类似物
  • 肾臟替代疗法
    • 血液透析
    • 腹膜透析
      • 自动化
      • 持续携带式
    • 移植

第九章末期肾功能衰竭治疗市场（依最终用户划分）

  • 透析中心
  • 居家医疗环境
  • 医院

第十章 按分销管道分類的末期肾功能衰竭治疗市场

  • 医院药房
  • 网路药房
  • 零售药房

第十一章末期肾功能衰竭治疗市场：依地区划分

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十二章 按组别末期肾功能衰竭治疗市场

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十三章 各国末期肾功能衰竭治疗市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十四章 美国：末期肾功能衰竭治疗市场

第十五章 中国：末期肾功能衰竭治疗市场

第十六章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Amgen Inc.
  • Asahi Kasei Corporation
  • AstraZeneca plc
  • B. Braun Melsungen AG
  • Baxter International Inc.
  • Bayer AG
  • Cantel Medical Corporation
  • DaVita Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Fresenius Kabi
  • Fresenius Medical Care AG & Co. KGaA
  • GlaxoSmithKline plc
  • JMS Co., Ltd.
  • Johnson & Johnson
  • Kyowa Kirin Co., Ltd.
  • Medtronic plc
  • Mitsubishi Tanabe Pharma Corporation
  • Nikkiso Co., Ltd.
  • Nipro Corporation
  • Novartis AG
  • NxStage Medical, Inc.
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Rockwell Medical, Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
  • Toray Medical Co., Ltd.
  • Vifor Pharma Group Ltd
Product Code: MRR-C36616F6997B

The End-stage Renal Disease Therapeutics Market was valued at USD 67.05 billion in 2025 and is projected to grow to USD 70.73 billion in 2026, with a CAGR of 4.17%, reaching USD 89.29 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 67.05 billion
Estimated Year [2026] USD 70.73 billion
Forecast Year [2032] USD 89.29 billion
CAGR (%) 4.17%

Comprehensive introduction to end-stage renal disease therapeutics highlighting evolving clinical priorities, patient journeys, and cross-disciplinary care integration

This executive introduction establishes a concise orientation to the clinical, operational, and commercial dimensions that define contemporary end-stage renal disease therapeutics. It frames priority patient populations, common comorbidities, and care pathway touchpoints while emphasizing the interplay between pharmacologic management and renal replacement modalities. By situating therapies within the continuum of care, the introduction highlights how shifts in practice patterns, technology diffusion, and payer expectations combine to reshape treatment decisions and provider responsibilities.

In addition, the introduction outlines the roles of multidisciplinary teams-nephrologists, dialysis nurses, transplant coordinators, and primary care clinicians-in coordinating long-term care. It also describes how patient preferences, particularly regarding quality of life and home-based options, are increasingly central to therapeutic selection and adherence strategies. Finally, the introduction sets expectations for the rest of the report by identifying major themes-innovation in drug classes, expansion of home dialysis, supply chain resilience, and evolving distribution channels-that will be explored in depth and tied back to actionable implications for clinical leaders, manufacturers, and health system executives.

Transformative shifts in clinical practice, reimbursement models, and technology-enabled home therapies reshaping patient access and clinician workflows across care settings

The landscape for end-stage renal disease is in the midst of several transformative shifts that affect clinicians, manufacturers, and health systems alike. Clinical practice is moving toward greater personalization of therapy, where treatment selection integrates patient comorbidity profiles, real-world adherence patterns, and the growing availability of home-based modalities. At the same time, reimbursement and policy levers are recalibrating incentives for care delivery, encouraging shorter in-center encounters, bundled payment approaches, and value-based arrangements that reward outcomes rather than volume.

Technological advances are accelerating change through improved dialysis equipment, telehealth-enabled monitoring, and digital adherence tools that link patients to care teams in real time. These innovations are complemented by evolving drug development strategies, including therapies that target mineral bone disease, anemia, and iron management with refined safety profiles and administration conveniences. As a result, provider workflows are adapting: care coordination demands more integrated data flows, supply chain practices prioritize just-in-time resilience, and commercial models increasingly emphasize integrated service offerings that combine devices, therapies, and digital support. These converging shifts are not isolated; rather, they interact to create new opportunities for differentiated patient outcomes and novel business models across the renal care ecosystem.

Anticipated cumulative implications of United States tariff developments in 2025 on supply chains, sourcing strategies, cost structures, and global procurement of renal therapeutics

The cumulative impact of United States tariff developments in 2025 will reverberate through procurement, manufacturing, and distribution practices relevant to renal therapeutics without altering the clinical rationale for treatment. Tariff changes influence the cost basis for imported active pharmaceutical ingredients, dialysis consumables, and capital equipment, prompting supply chain managers to reassess sourcing geographies and inventory policies. In response, stakeholders are likely to emphasize supplier diversification, nearshoring where feasible, and dual-sourcing strategies to reduce exposure to single-country disruptions.

Beyond sourcing, tariff dynamics also affect contractual arrangements with distributors and hospital purchasing groups. Procurement teams increasingly negotiate terms that allocate risk or include price adjustment provisions that trigger under specified tariff events. At the same time, manufacturers and distributors may accelerate localization of manufacturing for high-volume components or invest in tariff classification and customs optimization to mitigate incremental costs. Importantly, these operational responses feed into broader strategic choices: product launch sequencing, contract structuring for bundled services, and partnership models that aggregate purchasing power across health systems. Throughout, regulatory compliance and quality assurance remain non-negotiable, so mitigation efforts must preserve traceability and adherence to good manufacturing and distribution practices while seeking cost-efficiency.

Key segmentation insights synthesizing therapeutic classes, dialysis modalities, end-user delivery pathways, and distribution channels to inform product positioning

Key segmentation insights draw on the interplay between therapeutic categories, delivery modalities, and channel dynamics to reveal where clinical need, operational feasibility, and commercial opportunity converge. Based on therapy type, the landscape includes drug therapy and renal replacement therapy. Within drug therapy, important classes such as calcimimetics, erythropoiesis stimulating agents, iron therapies, phosphate binders, and vitamin D analogs each present distinct efficacy, safety, and administration trade-offs that influence formulary decisions and adherence support programs. Renal replacement therapy spans hemodialysis, peritoneal dialysis, and transplant, with hemodialysis further differentiated into home and in-center settings and peritoneal dialysis split between automated and continuous ambulatory approaches; these modality distinctions matter for device compatibility, training needs, and post-acute care coordination.

From an end-user perspective, treatment pathways are shaped by dialysis centers, home care settings, and hospitals, which have differing operational capabilities, staffing models, and procurement channels. Distribution pathways likewise influence access and service expectations, with hospital pharmacy, online pharmacy, and retail pharmacy options each providing distinct benefits for dispensing, reimbursement handling, and patient convenience. Taken together, these segmentation layers imply that successful product positioning requires aligning clinical messaging to therapy class, designing services that accommodate modality-specific workflows, and selecting distribution strategies that match the purchasing behavior and logistical capacities of dialysis centers, home care organizations, and hospitals.

Strategic regional perspectives across the Americas, Europe Middle East & Africa, and Asia-Pacific highlighting access dynamics, clinical infrastructure, and policy levers

Regional insights reveal how policy environments, clinical infrastructure, and patient demographics shape adoption patterns and operational practices across the Americas, Europe Middle East & Africa, and Asia-Pacific. In the Americas, care delivery typically balances advanced in-center dialysis capacity with growing interest in home therapies and transplant programs, driven by payers and integrated delivery networks that value coordinated chronic care management. Transitioning from this baseline, manufacturers and service providers must tailor engagement strategies to reflect diverse payer models and concentrated centers of excellence.

Across Europe Middle East & Africa, variations in public funding, regulatory approval pathways, and infrastructural maturity create heterogeneous access patterns; some markets prioritize centralized hospital-based care while others have progressive reimbursement for home-based modalities. Consequently, stakeholders often pursue differentiated go-to-market strategies that emphasize local partnerships and adaptable service bundles. In the Asia-Pacific region, demographic trends and rising chronic disease burdens intersect with rapid scale-up of dialysis capacity and an expanding private sector role, creating opportunities for innovative financing models, capacity-building programs, and digital solutions that support remote monitoring and workforce training. Together, these regional dynamics underscore the importance of customizing clinical support, supply chain models, and stakeholder engagement to regional policy, infrastructure, and patient preference profiles.

Competitive and partnership dynamics among leading manufacturers, technology providers, and service networks driving innovation, trial design, and commercialization strategies

Insights about key companies emphasize how competitive positioning, collaborative alliances, and service differentiation shape innovation trajectories and market behavior. Leading manufacturers and technology providers are increasingly integrating drug portfolios with devices and digital support to deliver bundled solutions that address both clinical outcomes and adherence barriers. This integration extends to trial design partnerships with academic centers and health systems, enabling pragmatic evidence generation that demonstrates real-world effectiveness in diverse care settings.

Partnerships between device makers, pharmaceutical firms, and third-party service organizations are also accelerating, focusing on patient monitoring, remote training for home modalities, and logistics optimization. These collaborations frequently aim to reduce total cost of care while enhancing patient-centered outcomes, making it easier for providers and payers to adopt new treatment approaches. Additionally, companies that invest in robust post-market surveillance and transparent safety reporting tend to build higher trust among clinicians and procurement teams, creating durable commercial advantages. Overall, the most successful corporate strategies combine clinical credibility, supply chain reliability, and an ability to co-create service models with healthcare delivery partners.

Actionable recommendations to align clinical development, supply resilience, and patient-centered delivery models for measurable operational and clinical improvements

Actionable recommendations encourage industry leaders to align clinical development, operational resilience, and patient-centered delivery to capture sustainable value and improve outcomes. First, prioritize modular product and service designs that can be adapted across hemodialysis, peritoneal dialysis, and transplant pathways, and ensure clinical evidence generation addresses modality-specific endpoints. Second, build supply chain resilience through diversified sourcing strategies, enhanced visibility into tier-one and tier-two suppliers, and contractual frameworks that distribute tariff and logistics risks while preserving quality controls.

Third, engage payers and provider networks early to co-design reimbursement models and value-based contracting pilots that reflect meaningful patient outcomes and utilization patterns. Fourth, invest in clinician and patient education programs that facilitate transition to home-based therapies, leveraging telehealth and digital adherence tools to maintain clinical oversight and reduce readmissions. Finally, pursue strategic partnerships-both local and regional-that accelerate market entry, support regulatory navigation, and localize manufacturing or service delivery where necessary. Implementing these recommendations requires cross-functional alignment between clinical development, commercial strategy, supply chain, and health economics teams to translate insights into measurable operational and clinical improvements.

Robust mixed-methods research methodology outlining data sources, stakeholder engagement, validation processes, and analytical frameworks used to ensure rigor and relevance

The research methodology rests on a mixed-methods approach that combines primary stakeholder engagement, secondary literature synthesis, and qualitative validation to ensure rigor and relevance. Primary engagement included structured interviews with clinicians, procurement specialists, payers, and technology partners to capture frontline perspectives on treatment selection, modality adoption, and distribution practices. These interviews informed the development of hypothesis-driven inquiry and enabled triangulation of operational pain points and innovation priorities.

Secondary synthesis drew on peer-reviewed clinical literature, regulatory guidance documents, and public policy announcements to contextualize clinical efficacy, safety considerations, and reimbursement trends. The analytical framework incorporated thematic coding of qualitative inputs, comparative assessments across therapy classes and modalities, and scenario-based analysis to evaluate supply chain and policy impacts. Validation steps included expert review panels and iterative feedback sessions with domain specialists to refine interpretations and ensure the final deliverables reflect both clinical realities and practical commercial considerations. Throughout the process, data integrity, transparency of assumptions, and reproducibility of analytical steps were prioritized to deliver actionable intelligence for decision-makers.

Concluding synthesis articulating unmet needs, translational gaps, and strategic inflection points to guide research and development, commercialization, and payer engagement plans

In conclusion, the end-stage renal disease therapeutics landscape is characterized by converging pressures and opportunities that require coordinated responses from clinical, commercial, and operational stakeholders. Unmet needs persist in the optimization of anemia management, mineral bone disease control, and patient-centered delivery across dialysis and transplant pathways, while translational gaps remain in moving device-enabled and digital interventions from pilot phases to routine clinical practice. Strategic inflection points include the scaling of home modalities, the integration of bundled solutions that combine therapies and services, and the reconfiguration of supply chains in light of tariff and geopolitical risks.

For decision-makers, the implications are clear: prioritize evidence generation that addresses real-world outcomes, structure partnerships that accelerate delivery capacity and patient access, and establish procurement and contractual practices that balance cost, quality, and resilience. By aligning R&D priorities with operational realities and payer expectations, organizations can better position themselves to deliver measurable clinical improvements and sustainable commercial performance. The synthesis presented here points to concrete areas where investment and collaboration will yield the greatest downstream impact on patient care and system efficiency.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. End-stage Renal Disease Therapeutics Market, by Therapy Type

  • 8.1. Drug Therapy
    • 8.1.1. Calcimimetics
    • 8.1.2. Erythropoiesis Stimulating Agents
    • 8.1.3. Iron Therapies
    • 8.1.4. Phosphate Binders
    • 8.1.5. Vitamin D Analogs
  • 8.2. Renal Replacement Therapy
    • 8.2.1. Hemodialysis
    • 8.2.2. Peritoneal Dialysis
      • 8.2.2.1. Automated
      • 8.2.2.2. Continuous Ambulatory
    • 8.2.3. Transplant

9. End-stage Renal Disease Therapeutics Market, by End User

  • 9.1. Dialysis Centers
  • 9.2. Home Care Settings
  • 9.3. Hospitals

10. End-stage Renal Disease Therapeutics Market, by Distribution Channel

  • 10.1. Hospital Pharmacy
  • 10.2. Online Pharmacy
  • 10.3. Retail Pharmacy

11. End-stage Renal Disease Therapeutics Market, by Region

  • 11.1. Americas
    • 11.1.1. North America
    • 11.1.2. Latin America
  • 11.2. Europe, Middle East & Africa
    • 11.2.1. Europe
    • 11.2.2. Middle East
    • 11.2.3. Africa
  • 11.3. Asia-Pacific

12. End-stage Renal Disease Therapeutics Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. End-stage Renal Disease Therapeutics Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. United States End-stage Renal Disease Therapeutics Market

15. China End-stage Renal Disease Therapeutics Market

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025
  • 16.5. Amgen Inc.
  • 16.6. Asahi Kasei Corporation
  • 16.7. AstraZeneca plc
  • 16.8. B. Braun Melsungen AG
  • 16.9. Baxter International Inc.
  • 16.10. Bayer AG
  • 16.11. Cantel Medical Corporation
  • 16.12. DaVita Inc.
  • 16.13. Eli Lilly and Company
  • 16.14. F. Hoffmann-La Roche Ltd
  • 16.15. Fresenius Kabi
  • 16.16. Fresenius Medical Care AG & Co. KGaA
  • 16.17. GlaxoSmithKline plc
  • 16.18. JMS Co., Ltd.
  • 16.19. Johnson & Johnson
  • 16.20. Kyowa Kirin Co., Ltd.
  • 16.21. Medtronic plc
  • 16.22. Mitsubishi Tanabe Pharma Corporation
  • 16.23. Nikkiso Co., Ltd.
  • 16.24. Nipro Corporation
  • 16.25. Novartis AG
  • 16.26. NxStage Medical, Inc.
  • 16.27. Otsuka Pharmaceutical Co., Ltd.
  • 16.28. Pfizer Inc.
  • 16.29. Rockwell Medical, Inc.
  • 16.30. Sanofi S.A.
  • 16.31. Takeda Pharmaceutical Company Limited
  • 16.32. Toray Medical Co., Ltd.
  • 16.33. Vifor Pharma Group Ltd

LIST OF FIGURES

  • FIGURE 1. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. UNITED STATES END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 11. CHINA END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY CALCIMIMETICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY CALCIMIMETICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY CALCIMIMETICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY ERYTHROPOIESIS STIMULATING AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY ERYTHROPOIESIS STIMULATING AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY ERYTHROPOIESIS STIMULATING AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY IRON THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY IRON THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY IRON THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY PHOSPHATE BINDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY PHOSPHATE BINDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY PHOSPHATE BINDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY VITAMIN D ANALOGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY VITAMIN D ANALOGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY VITAMIN D ANALOGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY RENAL REPLACEMENT THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY RENAL REPLACEMENT THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY RENAL REPLACEMENT THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY RENAL REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY HEMODIALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY HEMODIALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY HEMODIALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY PERITONEAL DIALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY PERITONEAL DIALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY PERITONEAL DIALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY AUTOMATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY AUTOMATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY AUTOMATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY CONTINUOUS AMBULATORY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY CONTINUOUS AMBULATORY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY CONTINUOUS AMBULATORY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY TRANSPLANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY TRANSPLANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY TRANSPLANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY DIALYSIS CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY DIALYSIS CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY DIALYSIS CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. AMERICAS END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 64. AMERICAS END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 65. AMERICAS END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 66. AMERICAS END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY RENAL REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 67. AMERICAS END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 70. NORTH AMERICA END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. NORTH AMERICA END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 72. NORTH AMERICA END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY RENAL REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 74. NORTH AMERICA END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 77. LATIN AMERICA END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. LATIN AMERICA END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. LATIN AMERICA END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 80. LATIN AMERICA END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY RENAL REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 81. LATIN AMERICA END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 82. LATIN AMERICA END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE, MIDDLE EAST & AFRICA END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY RENAL REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE, MIDDLE EAST & AFRICA END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE, MIDDLE EAST & AFRICA END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE, MIDDLE EAST & AFRICA END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY RENAL REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 98. MIDDLE EAST END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. MIDDLE EAST END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. MIDDLE EAST END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 101. MIDDLE EAST END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY RENAL REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 102. MIDDLE EAST END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 103. MIDDLE EAST END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. MIDDLE EAST END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 105. AFRICA END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. AFRICA END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. AFRICA END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 108. AFRICA END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY RENAL REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 109. AFRICA END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 110. AFRICA END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 111. AFRICA END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY RENAL REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. ASEAN END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. ASEAN END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. ASEAN END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 123. ASEAN END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY RENAL REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 124. ASEAN END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 125. ASEAN END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 126. ASEAN END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 127. GCC END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GCC END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. GCC END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 130. GCC END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY RENAL REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 131. GCC END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 132. GCC END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 133. GCC END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPEAN UNION END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPEAN UNION END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPEAN UNION END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPEAN UNION END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY RENAL REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPEAN UNION END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPEAN UNION END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPEAN UNION END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 141. BRICS END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. BRICS END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. BRICS END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 144. BRICS END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY RENAL REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 145. BRICS END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 146. BRICS END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 147. BRICS END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 148. G7 END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. G7 END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. G7 END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 151. G7 END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY RENAL REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 152. G7 END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 153. G7 END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 154. G7 END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 155. NATO END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. NATO END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. NATO END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 158. NATO END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY RENAL REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 159. NATO END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 160. NATO END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. NATO END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. UNITED STATES END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 164. UNITED STATES END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. UNITED STATES END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 166. UNITED STATES END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY RENAL REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 167. UNITED STATES END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 168. UNITED STATES END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 169. UNITED STATES END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 170. CHINA END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 171. CHINA END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. CHINA END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2018-2032 (USD MILLION)
  • TABLE 173. CHINA END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY RENAL REPLACEMENT THERAPY, 2018-2032 (USD MILLION)
  • TABLE 174. CHINA END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 175. CHINA END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. CHINA END-STAGE RENAL DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)